NasdaqGS:INVAPharmaceuticals
A Closer Look At Innoviva (INVA) Valuation As P/E And DCF Signal A Wide Potential Discount
Without a fresh headline catalyst today, Innoviva (INVA) is attracting attention mainly through its recent share performance, valuation metrics and underlying financial profile. Together, these factors give investors a compact snapshot of this US-based pharmaceutical developer.
See our latest analysis for Innoviva.
At a share price of $19.51, Innoviva’s recent 12.19% 90 day share price return contrasts with a weaker year to date move and a 10.35% 1 year total shareholder return. This suggests...